In phase 3, if COVAXIN is effective enough to prevent the disease. Out of 1000 people recruited to give vaccine to 50% of them & placebo to others: India is set to conduct a third-stage trial of COVAXIN vaccine to prevent biotech corona virus infection. 1000 people have been recruited for its trial. In Phase 3, researchers will see if COVAXIN is effective enough to prevent the disease. Of these, 50 percent will be given COVAXIN vaccine and 50 percent will be given Plesibo vaccine. Also Read – 33 trainee IAS officers met positive at Corona at Civil Services Training Academy, Mussoorie
Dr. E. Venkata Rao, Principal Investigator of COVAXIN Testing in Bhubaneswar said, “In Phase 3 we will see if COVAXIN is effective enough to prevent the disease.” Out of the 1000 people admitted, we will give 50% of them and others the vaccine for placebo. Dr. is posted in Institute of Medical Sciences and SUM Hospital. Also Read – Corona cases increase in Madhya Pradesh, more than 1500 new cases came out
In phase 3, indicative see if COVAXIN is effective enough to prevent the disease. Out of 1000 people recruited, providing give vaccine to 50% of them & placebo to others: Dr E Venkata Rao, Principal investigator of COVAXIN trial at Institute of Medical Sciences & SUM Hospital, Bhubaneswar pic.twitter.com/Uws9gfFfzB Also Read – 6608 new cases of corona infection were reported in Delhi, the total figure of the dead was 8,159
– ANI (@ANI) November 21, 2020
Bharat Biotech has admitted that its coronavirus vaccine covaxin had an adverse event during a Phase 1 trial in August when a patient was hospitalized with a dose of the vaccine candidate. However, Pharma later clarified that it reported the incident within 24 hours.
An adverse event occurred during the trial in the first phase during August 2020 and was reported to CDSCO-DCGI within 24 hours of its occurrence and confirmation. The adverse event was intensively investigated and determined as not related to the vaccine, Bharat Biotech issued a statement.